Non-steroidal anti-inflammatory drugs and the risk of psychosis

European Neuropsychopharmacology

Volumn 17, Issue 4, 2007, Pages 309-311

  Laan, W ^a   Selten, Jean Paul ^b   Grobbee, D E ^a   Smeets, H ^c   Kahn, René S ^b   Burger, Huibert ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c University Medical Center Groningen ^*  (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Inflammation; NSAID; ; Psychosis; ; Schizophrenia;

Indexed keywords

NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; GENDER; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK; SEX FACTORS;

EID: 33846489814     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.09.003     Document Type: Article

References (18)

1. Aleman A., Kahn R.S., and Selten J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Archives of General Psychiatry 60 6 (2003) 565-571
2. Barbui C., Ciuna A., Nose M., Patten S.B., Stegagno M., Burti L., Amaddeo F., and Tansella M. Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatrica Scandinavica 109 4 (2004) 275-278
3. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Colombo F., Zagliani A., and Clerici M. Cytokine profiles in drug-naive schizophrenic patients. Schizophrenia Research 47 2-3 (2001) 293-298
4. Chong J.Y., Rowland L.P., and Utiger R.D. Hashimoto Encephalopathy: syndrome or myth?. Archives of Neurology 60 2 (2003) 164-171
5. Das I., and Khan N.S. Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins, Leukotrienes and Essential Fatty Acids 58 3 (1998) 165-168
6. DeLisi L.E. Is there a viral or immune dysfunction etiology to schizophrenia? Re-evaluation a decade later. Schizophrenia Research 22 1 (1996) 1-4
7. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 28 Supplement 2 (2003) 17-54
8. Hanson D.R., and Gottesman I.I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Medical Genetics 6 (2005) 7
9. Jiang H.K., and Chang D.M. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clinical Rheumatology 18 4 (1999) 339-345
10. Korschenhausen D.A., Hampel H.J., Ackenheil M., Penning R., and Muller N. Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophrenia Research 19 2-3 (1996) 103-109
11. Maes M., Bosmans E., Calabrese J., Smith R., and Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research 29 2 (1995) 141-152
12. Mors O., Mortensen P.B., and Ewald H. A population-based register study of the association between schizophrenia and rheumatoid arthritis. Schizophrenia Research 40 1 (1999) 67-74
13. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., Ulmschneider M., Engel R.R., Moller H.J., and Schwarz M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 159 6 (2002) 1029-1034
14. Muller N., Ulmschneider M., Scheppach C., Schwarz M.J., Ackenheil M., Moller H.J., Gruber R., and Riedel M. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. European Archives of Psychiatry and Clinical Neuroscience 254 1 (2004) 14-22
15. Naudin J., Capo C., Giusano B., Mege J.L., and Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-[alpha] in schizophrenia?. Schizophrenia Research 26 2-3 (1997) 227-233
16. Riecher-Rössler. Oestrogen effects in schizophrenia and their potential therapeutic implications - review. Archives of Women's Mental Health 5 3 (2002) 111-118
17. Rijcken C.A., Boelema G.J., Slooff C.J., Beuger P.J., Tanja T.A., and de Jong-van den Berg L.T. Off-label use of antipsychotics in the community pharmacy: the sex differences. Pharmacopsychiatry 36 5 (2003) 187-191
18. Schwarz M.J., Chiang S., Muller N., and Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain, Behavior, and Immunity 15 4 (2001) 340-370